Riskpilot← Back to searchSign inGet full accessEpione Medicine ApS
APSActiveCVR 41812052Kanalholmen 14LWholesale of pharmaceutical and medical goods · NACE 4646Est. 202046 employeesEpionemedicine.com
Revenue 2024
DKK 31,3M
+1115% vs 2023
EBITDA margin
83.0%
+19597% vs 2023
Equity ratio
39.5%
Financial strength
Net profit 2024
DKK 19M
+3036% vs 2023
| Revenue | DKK 31,3M | +1115% |
| EBITDA | DKK 26M | +19597% |
| Net profit | DKK 19M | +3036% |
| Total assets | DKK 48,3M | +459% |
| Equity | DKK 19,1M | +66304% |
| Employees | 46 | — |
Legal name
Epione Medicine ApS
CVR number
41812052
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
2. november 2020
Share capital
DKK 441.250
Employees
46 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af Emil Birk Johannsen og Jakob Skovbjerg Kjeldgaard
Company purpose
Virksomhedens formål er engroshandel med medicinalvarer
Address
Kanalholmen 14L
Phone
+4528603833
Email
info@epionemedicine.com
Website
Epionemedicine.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | -392 | 2.580 | 31.344 |
| Staff expenses | -9 | -2.448 | -5.339 |
| EBITDA | -401 | 132 | 26.005 |
| Depreciation & amort. | -35 | -396 | -530 |
| EBIT | -436 | -264 | 25.476 |
| Net financials | -28 | -550 | -1.005 |
| Profit before tax | -465 | -814 | 24.471 |
| Tax | -102 | -165 | 5.426 |
| Net profit | -363 | -649 | 19.045 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 1.261 | 8.629 | 48.252 |
| Equity | 17 | 29 | 19.074 |
| Long-term debt | 769 | 1.104 | 1.243 |
| Short-term debt | 471 | 7.496 | 27.131 |
| Total debt | 1.240 | 8.600 | 28.375 |
EBITDA margin
83.0%
This company
15.8%
Market median
+425% vs market
20222024
Equity ratio
39.5%
This company
38.2%
Market median
+3% vs market
20222024
Return on equity
99.8%
This company
18.4%
Market median
+442% vs market
20222024
Net profit margin
60.8%
This company
8.1%
Market median
+651% vs market
20222024
Asset turnover
0.65×
This company
1.12×
Market median
-42% vs market
20222024
Debt / equity
1.53×
This company
0.62×
Market median
-147% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JF Management | Management | 2022 |
EB Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2025 | |
| Chairman | 2025 | |
| Board of Directors | 2026 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.33–49.99% | 33.33–49.99% | 2022 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2022 | |
| Company | 20–24.99% | 20–24.99% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Jakob SK Holding ApS
Epione Medicine ApS Board members of Epione Medicine ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jakob Flinch Skovbjerg | Management | 0 companies |
| Emil Birk Johannsen | Chief Executive Officer | 0 companies |
| Leon Svejgaard Pedersen | Board of Directors | 0 companies |
| Steen Ulf Jensen | Chairman | 0 companies |
| Nikolaj Friis Krøyer | Board of Directors | 0 companies |